These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28229846)

  • 21. Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report.
    Cherrez-Ojeda I; Vanegas E; Felix M; Mata VL; Cherrez A
    BMC Dermatol; 2018 Oct; 18(1):8. PubMed ID: 30359231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urticaria: A comprehensive review: Treatment of chronic urticaria, special populations, and disease outcomes.
    Antia C; Baquerizo K; Korman A; Alikhan A; Bernstein JA
    J Am Acad Dermatol; 2018 Oct; 79(4):617-633. PubMed ID: 30241624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series.
    Ari A; Levy Y; Segal N; Maoz-Segal R; Benor S; Broides A; Horev A; Epstein-Rigbi N; Agmon-Levin N; Marcus N
    Pediatr Dermatol; 2020 Nov; 37(6):1051-1054. PubMed ID: 32951239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis.
    Ferrer M; Giménez-Arnau A; Saldana D; Janssens N; Balp MM; Khalil S; Risson V
    J Allergy Clin Immunol Pract; 2018; 6(4):1191-1197.e5. PubMed ID: 29655772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic Urticaria: An Overview of Treatment and Recent Patents.
    Hon KL; Leung AKC; Ng WGG; Loo SK
    Recent Pat Inflamm Allergy Drug Discov; 2019; 13(1):27-37. PubMed ID: 30924425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What are the effects of omalizumab in refractory chronic spontaneous urticaria?
    López M; Navajas-Galimany L
    Medwave; 2015 Dec; 15 Suppl 3():e6346. PubMed ID: 26731420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
    Giménez-Arnau AM
    Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.
    Giménez-Arnau AM; Toubi E; Marsland AM; Maurer M
    J Eur Acad Dermatol Venereol; 2016 Jul; 30 Suppl 5():25-32. PubMed ID: 27286500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic Urticaria.
    Hsu JI; Hsu S
    Skinmed; 2022; 20(5):364-366. PubMed ID: 36314703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic Urticaria.
    Hsu JI; Hsu S
    Skinmed; 2022; 20(4):364-366. PubMed ID: 36314621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
    Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
    Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature.
    Kasperska-Zajac A; Jarząb J; Żerdzińska A; Bąk K; Grzanka A
    Int J Immunopathol Pharmacol; 2016 Jun; 29(2):320-8. PubMed ID: 26729404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
    Kaplan A; Ferrer M; Bernstein JA; Antonova E; Trzaskoma B; Raimundo K; Rosén K; Omachi TA; Khalil S; Zazzali JL
    J Allergy Clin Immunol; 2016 Feb; 137(2):474-81. PubMed ID: 26483177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria.
    Giménez Arnau AM; Valero Santiago A; Bartra Tomás J; Jáuregui Presa I; Labrador Horrillo M; Miquel Miquel FJ; Ortiz de Frutos J; Sastre J; Silvestre Salvador JF; Ferrer Puga M
    J Investig Allergol Clin Immunol; 2019; 29(5):338-348. PubMed ID: 30222111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
    Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K
    J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of omalizumab in refractory chronic spontaneous urticaria: real-life experience in Turkey.
    Bulur I; Bulbul Baskan E; Ozdemir M; Balevi A; Kocatürk Göncü E; Altunay I; Gönül M; Ergin C; Ertam İ; Erdoğan HK; Bilgin M; Mustafa Teoman E
    Acta Dermatovenerol Alp Pannonica Adriat; 2018 Sep; 27(3):121-126. PubMed ID: 30244261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delayed Pressure Urticaria: Clinical and Diagnostic Features and Response to Omalizumab.
    Veleiro-Pérez B; Alba-Muñoz J; Pérez-Quintero O; Rodríguez RL; Calvín-Lamas M; Parra-Arrondo A
    Int Arch Allergy Immunol; 2022; 183(10):1089-1094. PubMed ID: 35609554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Omalizumab: therapeutic option in chronic spontaneous urticaria difficult to control with associated vasculitis, report of three cases].
    Díez LS; Tamayo LM; Cardona R
    Biomedica; 2013; 33(4):503-12. PubMed ID: 24652205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with omalizumab or cyclosporine for resistant chronic spontaneous urticaria.
    Koski R; Kennedy KK
    Ann Allergy Asthma Immunol; 2017 Nov; 119(5):397-401. PubMed ID: 29150066
    [No Abstract]   [Full Text] [Related]  

  • 40. Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria.
    Graham J; McBride D; Stull D; Halliday A; Alexopoulos ST; Balp MM; Griffiths M; Agirrezabal I; Zuberbier T; Brennan A
    Pharmacoeconomics; 2016 Aug; 34(8):815-27. PubMed ID: 27209583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.